DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy Volunteers

Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pulmonary Disease, Chronic Obstructive; Healthy Subjects

Intervention: GSK961081 (Drug); Propanolol (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline


Study will investigate the pharmacodynamics of a dual pharmacophore in which a combination of GSK961081 and Propanolol is used to give a total effect of bronchodilation.

Clinical Details

Official title: A Study to Investigate the Relative Pharmacological Activity of Aninhaled B2-agonist/Anticholinergic Dual Pharmacophore Inhealthy Volunteers

Study design: Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome: To assess the bronchodilation of single doses of GSK961081 over 24 hours following ß blockade with the ß antagonist propranolol as measured by sGaw in healthy subjects.

Secondary outcome:

Assess safety of GSK961081 after single doses of it with&without ß blockade with propranolol as measured by specific indicators

Adverse events, clinical laboratory safety tests, FEV1, vital signs, 12-lead ECG parameters, blood glucose and serum potassium.

Propranolol and GSK961081blood levels to derive pharmacokinetics

Assess systemic pharmacokinetics of GSK961081 and propranolol after single doses of both


Minimum age: 18 Years. Maximum age: 50 Years. Gender(s): Male.


Inclusion Criteria:

- Healthy adult males aged between 18 and 50 years.

- Body mass index within the range 19-29. 9 kg/m2.

- FEV1 ≥ 80% predicted and a FEV1/ Forced Vital Capacity (FVC) ratio ≥ 0. 7

- Signed and dated written informed consent is obtained from the subject

- The subject is able to understand and comply with the protocol requirements,

instructions and protocol-stated restrictions.

- The subject has an increase in sGAW of ≥15% over pre-dose baseline within 2 h of

administration of 400 µg salbutamol by MDI inhaler at screening or in the 3 months before screening.

- The subject has an increase in sGAW of ≥25% over pre-dose baseline within 2 h

following 80 µg ipratropium bromide at screening or in the 3 months before screening.

- Subjects who are current non-smokers who have not used any tobacco products in the

6-month period preceding the screening visit and have a pack history of ≥ 10 pack years. Exclusion Criteria:

- Any clinically relevant abnormality identified at the screening medical assessment

(physical examination/medical history), clinical laboratory tests, or ECG (12-lead or Holter).

- A history of respiratory disease (i. e. history of asthmatic symptoms).

- Clinically significant abnormal 12 lead ECG at

- A subject in whom ipratropium bromide, salbutamol or propranolol are contraindicated.

- A supine blood pressure that is persistently higher than 140/90 millimetres of

mercury (mmHg) at screening.

- A supine mean heart rate outside the range 45-90 beats per minute (bpm) at screening.

- The subject has donated a unit of blood within the 56 days or intends to donate

within 56 days after completing the study.

- The subject is currently taking regular (or course of) medication whether prescribed

or not (with the exception of contraceptives, including vitamins and herbal remedies such as St John's Wort.

- The subject has used prescription or non-prescription drugs, including vitamins,

herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (which ever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and medical monitor the medication will not interfere with the study procedures or compromise subject safety.

- The subject has participated in a clinical study with a New Chemical Entity (NCE)

within the past 3 months.

- Exposure to more than four new chemical entities within 12 months prior to the first

dosing day.

- The subject is infected with the Hepatitis B, Hepatitis C, or HIV virus.

- The subject has a positive pre-study urine cotinine/ breath carbon monoxide test,

urine drug/urine alcohol screen.

- A history of regular alcohol consumption exceeding weekly intake of alcohol greater

than 28 units for males, or an average daily intake of greater than 4 units.

- Are unable to use the inhaler correctly.

- The subject has a history of drug or other allergy, which, in the opinion of the

Investigator, contraindicates their participation.

- The subject has had a lower respiratory tract infection within 4 weeks of study


- Subject is unable to perform the sGAW measurements

Locations and Contacts

GSK Investigational Site, Harrow, Middlesex HA1 3UJ, United Kingdom
Additional Information

Starting date: March 2008
Last updated: May 31, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017